ASCOT

(redirected from Anglo-Scandinavian Cardiac Outcomes Trial)
AcronymDefinition
ASCOTAnglo-Scandinavian Cardiac Outcomes Trial
ASCOTA Severity Characterization of Trauma
ASCOTAustralian Standing Committee on Tourism
ASCOTAtmospheric Studies in Complex Terrain
ASCOTAdvanced Simulation Combat Operations Trainer (PLEXSYS Interface Products, Inc.)
ASCOTAssociated Students for Career Orientation in Telecommunications (MSU)
ASCOTAutomated System for Cataloging and Ordering Textiles
ASCOTAmerican Share Coalition on Transplantation
ASCOTAirspace Control and Operations Trainer
ASCOTAtmospheric Simulations Over Complex Terrain
ASCOTAsset Swap Convertible Option Trade (finance)
References in periodicals archive ?
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial.
This new, prespecified analysis of data collected in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) also identified a fasting plasma glucose level above 5 mmol/L (90 mg/dL) as the most powerful baseline predictor of a hypertensive patient's risk of developing diabetes, producing a 5.
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, and Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the "winning" strategy for cardiovascular protection was the one backed by the trial's commercial sponsors and also the one that resulted in significantly lower blood pressure than the comparator, he said.
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, and Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the "winning" strategy for CV protection was the one backed by the trial's commercial sponsors--and also the one that resulted in significantly lower blood pressure than the comparator, he said.
Amlodipine's ability to substantially reduce central aortic pressure is likely a major reason why the clinical results from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) showed that patients treated with an amlodipine-based regimen had a 16% relative reduction in the incidence of total cardiovascular events and procedures, compared with patients treated with an atenolol-based regimen during an average follow-up of 5.
A new analysis of data that was collected from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) demonstrated a "much more dramatic risk reduction in patients treated with amlodipine and atorvastatin, compared with those treated with atenolol and atorvastatin," Peter S.
This analysis used data collected from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) found a 36% reduction in risk for fatal and nonfatal MI after 3.
In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the incidence of the primary study end point--fatal coronary heart disease and nonfatal MI--was 6.